Aakaar Medical Technologies hits lower circuit on debut; stock disappoints investors with the worst SME listing performance

The aesthetic medical products specialist, Aakaar Medical Technologies Limited, delivered one of the worst debuts on the National Stock Exchange SME platform on June 27, 2025. After closing its IPO bidding between June 20 - June 24, 2025, the company commenced trading with an initial premium but immediately crashed to hit the lower circuit limit, reflecting severe market rejection despite the growing aesthetic medicine sector. This book-building IPO raised ₹27.00 crore with a modest subscription of 2.28 times, and the catastrophic listing performance validated investor concerns about financial sustainability and aggressive pricing as the stock plummeted from its opening price to deliver significant losses within hours of trading.

Don’t Miss Out on the Next Big IPO – Invest With Just a Few Clicks!

Open Account Now

Aakaar Medical Technologies IPO Listing Details

Aakaar Medical Technologies Limited launched its IPO through the book-building process with shares priced at ₹72 per share. The minimum investment required was 1,600 shares costing ₹1,15,200 at the cutoff price. The IPO received a subdued response with an overall subscription of 2.28 times - QIB segment at 3.51 times, retail at 1.93 times, and NII at a modest 1.48 times by the final day of bidding, demonstrating limited investor enthusiasm across all categories. Aakaar Medical Technologies' share price opened at ₹75 on NSE SME but immediately crashed to hit the lower circuit of ₹71.25, delivering a disappointing -1.04% loss from the issue price of ₹72. The stock's catastrophic debut performance represented one of the worst SME listings in recent memory, validating market concerns about valuation and business sustainability.

Listing Price: The Aakaar Medical Technologies share price opened at ₹75 on NSE SME on June 27, 2025, initially showing a 4.17% premium from the issue price of ₹72, but immediately crashed to the lower circuit of ₹71.25, delivering a devastating loss for investors.

First-Day Trading Performance Outlook

Aakaar Medical Technologies IPO experienced a catastrophic market debut on June 27, 2025, opening at ₹75 but immediately facing massive selling pressure that drove the stock to hit the lower circuit limit of ₹71.25, representing a 5% intraday decline. The dramatic price collapse from opening to lower circuit within hours reflected complete investor loss of confidence and validated concerns about the company's business model and valuation.

Utilisation of IPO Proceeds

Aakaar Medical Technologies plans to utilise the ₹27.00 crore raised from the fresh issue primarily for working capital enhancement to support business operations and growth initiatives.

• Working Capital Requirements: ₹20.35 crore allocated for funding working capital requirements to support inventory management, business operations, and expansion activities across the aesthetic medical products business
• General Corporate Purposes: Remaining funds are designated for general corporate purposes to support strategic initiatives, operational requirements, and business development activities

Financial Performance of Aakaar Medical Technologies IPO

Aakaar Medical Technologies has demonstrated growth in recent periods, though with significant concerns about sustainability and authenticity of improvements, as validated by the catastrophic listing performance:

• Revenue: ₹61.76 crore for FY25, showing solid growth trajectory with 33% increase from ₹46.27 crore in FY24 and 88% growth from ₹32.88 crore in FY23, though sudden surge raises sustainability questions confirmed by market rejection
• Net Profit: ₹6.04 crore in FY25, demonstrating significant profitability improvement with 110% growth from ₹2.87 crore in FY24 and 181% growth from ₹2.15 crore in FY23, though a substantial jump in the pre-IPO year raises concerns validated by the immediate lower circuit
• Financial Metrics: The company shows a strong ROCE of 21.02%, a robust RoNW of 33.81%, a concerning debt-to-equity ratio of 0.98, a healthy PAT margin of 9.81%, and an EBITDA margin of 15.81%, though elevated debt levels. 

Aakaar Medical Technologies represents a cautionary tale in the aesthetic medical products sector, with its immediate lower circuit hit delivering one of the worst SME debuts in recent memory. The stock's catastrophic performance, crashing from ₹75 opening to ₹71.25 lower circuit within hours, validates significant concerns over financial sustainability, aggressive valuation, and competitive challenges.